SCHEMBL514216

SCHEMBL514216

[CH2]COCC[Si](C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701636 0.83 ALOX15 (0.32)
SCHEMBL430949 0.81
SCHEMBL1289421 0.78 MEN1 (0.32)
SCHEMBL419805 0.78 MEN1 (0.32)
SCHEMBL6965978 0.74
SCHEMBL292853 0.73
SCHEMBL431029 0.73
SCHEMBL6959387 0.72
SCHEMBL9939446 0.71
SCHEMBL5579 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110678447-B Modified nucleic acid monomer compounds and oligonucleotide analogues 卫材R&D管理有限公司 2023-12-12 CN claimed
EP-3630738-A1 PROCESS FOR THE PRODUCTION OF OZANIMOD Egis Gyógyszergyár Zrt. (HU) 2020-04-08 EP claimed
WO-2018215807-A1 PROCESS FOR THE PRODUCTION OF OZANIMOD EGIS GYÓGYSZERGYÁR ZRT. (HU) 2018-11-29 WO claimed
US-20120077798-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2012-03-29 US claimed
EP-2288610-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS Incyte Corporation (US) 2011-03-02 EP claimed
WO-2009114512-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 WO claimed
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 US claimed
EP-0711773-A1 HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE SUNTORY LIMITED (JP) 1996-05-15 EP claimed
EP-4362933-A1 COMPLEMENT INHIBITION Apellis Pharmaceuticals, Inc. (US) 2024-05-08 EP disclosed
WO-2024054669-A2 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID-BASED THERAPEUTICS AND METHODS THEREOF NANOTECH PHARMA INC. (US) 2024-03-14 WO disclosed
US-20240059679-A1 GLP-1 Receptor Agonists and Uses Thereof PFIZER INC. (US) 2024-02-22 US disclosed
CN-110678447-B Modified nucleic acid monomer compounds and oligonucleotide analogues 卫材R&D管理有限公司 2023-12-12 CN disclosed
EP-3643706-B1 MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES EISAI R&D MAN CO LTD (JP) 2023-11-15 EP disclosed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
US-6693193-B1 COUPLING AN N- AND O-PROTECTED 2,3-DIHYDROXY-PYRROLIDINE TO THE 2-POSITION AND DEPROTECTING INDUSTRIAL RESEARCH LIMITED (NZ) 2004-02-17 US disclosed
US-6084081-A Lewis X derivatives DAIKIN INDUSTRIES, LTD. (JP) 2000-07-04 US disclosed
WO-1999065881-A1 HETEROCYCLIC COMPOUNDS AS HYPOGLYCEMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1999-12-23 WO disclosed
EP-0930315-A1 LEWIS X DERIVATIVES DAIKIN INDUSTRIES, LTD. (JP) 1999-07-21 EP disclosed
WO-1994003439-A1 ANTIPROLIFERATIVE TRICYCLIC COMPOUNDS AGOURON PHARMACEUTICALS, INC. (US) 1994-02-17 WO disclosed
EP-0437508-A4 NON-PEPTIDE RENIN INHIBITORS 1991-11-06 EP disclosed